-- Journey Medical (DERM) secured a contract with a third major group purchasing organization, expanding access to its Emrosi rosacea treatment.
The agreement lifts payer coverage to 85% of people with commercial insurance in the US, up to more than 150 million individuals from 100 million, the company said Tuesday in a statement.
Price: $5.11, Change: $-0.09, Percent Change: -1.64%